Glucose B. Braun

Glucose B. Braun is an intravenous solution for injection that contains glucose monohydrate as the sole active ingredient. It is supplied as a sterile aqueous solution without a specified concentration and is intended for clinical use in hospital within the European market. Classified as an excipient/solvent, the product is prescription‑only and provides an osmotic source of carbohydrate adequately for patients needing parenteral nutrition or fluid replacement.

Glucose B. Braun is used as an intravenous carbohydrate source in a variety of clinical situations where rapid energy provision or fluid balance is required.

- To supply glucose for energy during parenteral nutrition. - As an osmotic agent in intravenous fluid therapy to maintain plasma volume. - For correction of hypoglycemia when oral intake is not possible. - As a diluent for compatible intravenous medications requiring a carbohydrate carrier. - In perioperative settings to prevent intra‑operative hypoglycemia. - To support glucose levels during prolonged fasting or critical illness. - As part of electrolyte replacement solutions where glucose is required for cellular metabolism.

Glucose B. Braun, like other intravenous glucose solutions, may be associated with a range of adverse reactions that vary in frequency and severity.

Common: - Transient hyperglycemia when administered in excess. - Local irritation or pain at the injection site. - Mild electrolyte shifts, particularly sodium or potassium changes. - Nausea or vomiting in susceptible individuals. - Mild headache reported during rapid infusion. - Temporary increase in serum osmolality.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypotension due to rapid osmotic shifts. - Allergic or anaphylactoid reactions such as rash, urticaria, or bronchospasm. - Metabolic acidosis in patients with impaired renal function. - Fluid overload leading to pulmonary edema in patients with cardiac dysfunction.

When using Glucose B. Braun, clinicians should observe several precautions to minimize risks and ensure appropriate therapeutic outcomes.

- Verify patient’s blood glucose level before and after administration. - Adjust infusion rate according to individual fluid and electrolyte status. - Use aseptic technique to prevent contamination of the solution. - Monitor for signs of hyperglycemia, especially in diabetic patients. - Assess cardiac and renal function prior to large-volume administration. - Avoid rapid bolus injection unless specifically indicated. - Ensure compatibility with any co‑administered intravenous drugs before mixing. - Document the total daily glucose load to avoid exceeding recommended caloric limits.

Glucose B. Braun may interact with certain medications or clinical conditions; awareness of these interactions helps guide safe administration.

Avoid: - Concurrent rapid infusion of hypertonic saline solutions, which can exacerbate osmotic shifts. - Co‑administration with insulin infusions without appropriate glucose monitoring.

Use with caution: - Use with diuretics, as changes in fluid balance may affect glucose concentration. - Caution when combined with beta‑blockers, which can mask hypoglycemia symptoms. - Use with caution in patients receiving total parenteral nutrition, to avoid excessive carbohydrate load. - Monitor closely when given with drugs that affect renal clearance, such as aminoglycosides. - Consider adjusting the infusion rate when the patient is on corticosteroid therapy, which can increase glucose production.